Braveheart Bio Balance Sheet
NASDAQ: BRVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Braveheart Bio has no annual balance sheet on file yet, so quarterly figures are shown instead.
Braveheart Bio financial position
As of Jun 30, 2026, Braveheart Bio reported total assets of $127.0 million against total liabilities of $9.3 million. Shareholders' equity was negative at -$95.9 million, meaning liabilities exceed assets; this is often the result of large share buybacks or accumulated losses. The company held $122.8 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 13.63, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Braveheart Bio balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q? 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Cash & Equivalents | 122.83M | — | 2.00K | — |
| Total Current Assets | 123.44M | — | — | — |
| Property, Plant & Equipment | 23.00K | — | — | — |
| Total Assets | 126.96M | — | — | — |
| Accounts Payable | 2.67M | — | — | — |
| Total Current Liabilities | 9.06M | — | — | — |
| Total Liabilities | 9.34M | — | — | — |
| Shareholders' Equity | -95.91M | -78.39M | -477.00K | -99.00K |
| Retained Earnings | -95.91M | — | — | — |
| Net Cash (Debt) | 122.83M | — | 2.00K | — |
| Shares Outstanding | 7.54M | — | — | — |
This table shows 4 quarterly periods of Braveheart Bio's balance sheet, from Q2 2026 back to Q? 2025, across 11 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow BRVE's reporting calendar. What is a balance sheet?